iCardiac Technologies announced the implementation of its quality metric--Method Bias Sensitivity (MBS)--into its Phase I QT assessment services. The metric compares the automated measurements from a timepoint to the measurements/values derived by that core lab’s methodology that was used for that particular study. Other metrics are under discussion by the Cardiac Safety Research Consortium members, however, iCardiac is implementing its metric after the ICH E14 http://www.appliedclinicaltrialsonline.com/alternative-path-tqt-studies approved a lower-cost approach to TQT studies for cardiac safety assessment.
Read the full release here
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.